VNRX vs. TKNO, ABIO, AWH, ICCC, OCX, ACHV, YS, CGTX, CNTB, and ATHA
Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Alpha Teknova (TKNO), ARCA biopharma (ABIO), Aspira Women's Health (AWH), ImmuCell (ICCC), OncoCyte (OCX), Achieve Life Sciences (ACHV), YS Biopharma (YS), Cognition Therapeutics (CGTX), Connect Biopharma (CNTB), and Athira Pharma (ATHA). These companies are all part of the "medical" sector.
VolitionRx (NYSE:VNRX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
Alpha Teknova received 3 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 30.00% of users gave Alpha Teknova an outperform vote while only 27.27% of users gave VolitionRx an outperform vote.
In the previous week, Alpha Teknova had 2 more articles in the media than VolitionRx. MarketBeat recorded 3 mentions for Alpha Teknova and 1 mentions for VolitionRx. VolitionRx's average media sentiment score of 0.59 beat Alpha Teknova's score of 0.00 indicating that VolitionRx is being referred to more favorably in the media.
8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 15.4% of VolitionRx shares are owned by company insiders. Comparatively, 15.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
VolitionRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Alpha Teknova has a net margin of -100.26% compared to VolitionRx's net margin of -4,557.29%. VolitionRx's return on equity of 0.00% beat Alpha Teknova's return on equity.
VolitionRx has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
VolitionRx currently has a consensus price target of $2.50, indicating a potential upside of 247.22%. Given VolitionRx's stronger consensus rating and higher possible upside, equities research analysts plainly believe VolitionRx is more favorable than Alpha Teknova.
Summary
VolitionRx beats Alpha Teknova on 11 of the 18 factors compared between the two stocks.
Get VolitionRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VolitionRx Competitors List
Related Companies and Tools
